2. Academic Validation
  3. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

  • J Infect Dis. 1997 Nov;176(5):1215-24. doi: 10.1086/514115.
S Johnson 1,  C Oliver,  G A Prince,  V G Hemming,  D S Pfarr,  S C Wang,  M Dormitzer,  J O'Grady,  S Koenig,  J K Tamura,  R Woods,  G Bansal,  D Couchenour,  E Tsao,  W C Hall,  J F Young
Affiliations

Affiliation

  • 1 MedImmune Inc., Gaithersburg, Maryland 20878, USA.
PMID: 9359721 DOI: 10.1086/514115
Abstract

Neutralizing polyclonal antibody to respiratory syncytial virus (RSV) has been shown to be an effective prophylactic agent when administered intravenously in high-risk infants. This study describes the generation of a humanized monoclonal antibody, MEDI-493, that recognizes a conserved neutralizing epitope on the F glycoprotein of RSV. The affinity of MEDI-493 was found to be equal to or slightly better than an isotype-matched chimeric derivative of the parent antibody. In plaque reduction, microneutralization, and fusion-inhibition assays, MEDI-493 was significantly more potent than the polyclonal preparation. Broad neutralization of a panel of 57 clinical isolates of the RSV A and B subtypes was demonstrated. Pretreatment of cotton rats with MEDI-493 resulted in 99% reduction of lung RSV titers at a dose of 2.5 mg/kg, corresponding to a serum concentration of 25-30 microg/mL. Further, MEDI-493 did not induce increased RSV Infection or pathology in either a primary or a secondary challenge.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z